Drug Profile
Research programme: skin disorders therapeutics - Serentis
Alternative Names: SRD-285; SRD-326Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Serentis
- Class Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Raynaud's disease; Wounds
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Raynaud's-disease in United Kingdom (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Wounds in United Kingdom (Topical)
- 04 Mar 2009 Preclinical trials in Wounds in United Kingdom (Topical)